Pfizer Inc.

NYSE:PFE  
52.47
+1.82 (+3.59%)
5:09:00 PM EDT: $52.42 -0.05 (-0.10%)
Products

Pfizer Granted FDA Breakthrough Therapy Designation For Respiratory Syncytial Virus Vaccine Candidate For Prevention Of RSV In Older Adults

Published: 03/24/2022 10:56 GMT
Pfizer Inc. (PFE) - Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of Rsv in Older Adults.